Open Access

Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis

  • Authors:
    • Jun-Feng Chen
    • Bi-Xia Yu
    • Rui Yu
    • Liang Ma
    • Xiu-Yi Lv
    • Yue Cheng
    • Qi Ma
  • View Affiliations

  • Published online on: January 5, 2017     https://doi.org/10.3892/or.2017.5356
  • Pages: 721-728
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Epirubicin (EPI) is one of the most used intravesical chemotherapy agents after transurethral resection to non-muscle invasive bladder tumors (NMIBC) to prevent cancer recurrence and progression. However, even after resection of bladder tumors and intravesical chemotherapy, half of them will recur and progress. RON is a membrane tyrosine kinase receptor usually overexpressed in bladder cancer cells and associated with poor pathological features. This study aims to investigate the effects of anti-RON monoclonal antibody Zt/g4 on the chemosensitivity of bladder cells to EPI. After Zt/g4 treatment, cell cytotoxicity was significantly increased and cell invasion was markedly suppressed in EPI-treated bladder cancer cells. Further investigation indicated that combing Zt/g4 with EPI promoted cell G1/S-phase arrest and apoptosis, which are the potential mechanisms that RON signaling inhibition enhances chemosensitivity of EPI. Thus, combing antibody-based RON targeted therapy enhances the therapeutic effects of intravesical chemotherapy, which provides new strategy for further improvement of NMIBC patient outcomes.
View Figures
View References

Related Articles

Journal Cover

February-2017
Volume 37 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen J, Yu B, Yu R, Ma L, Lv X, Cheng Y and Ma Q: Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis. Oncol Rep 37: 721-728, 2017.
APA
Chen, J., Yu, B., Yu, R., Ma, L., Lv, X., Cheng, Y., & Ma, Q. (2017). Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis. Oncology Reports, 37, 721-728. https://doi.org/10.3892/or.2017.5356
MLA
Chen, J., Yu, B., Yu, R., Ma, L., Lv, X., Cheng, Y., Ma, Q."Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis". Oncology Reports 37.2 (2017): 721-728.
Chicago
Chen, J., Yu, B., Yu, R., Ma, L., Lv, X., Cheng, Y., Ma, Q."Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis". Oncology Reports 37, no. 2 (2017): 721-728. https://doi.org/10.3892/or.2017.5356